Lv21
190 积分 2022-03-06 加入
Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
6小时前
求助中
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan
2个月前
已完结
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
2个月前
已完结
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage
2个月前
已完结
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)
6个月前
已完结
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
6个月前
已完结
Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC)
6个月前
已完结
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status
6个月前
已完结
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
6个月前
已完结
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
6个月前
已完结
皖公网安备34019202002308
